What age is the quadrivalent cervical cancer vaccine suitable for?

The quadrivalent cervical cancer vaccine is suitable for women aged 20-45. The quadrivalent HPV vaccine is mainly used to prevent cervical cancer and genital warts caused by HPV types 16, 18, 6, and 11. The vaccination age range must strictly follow the recommendations in the instructions.

The applicable age of the quadrivalent HPV vaccine is determined based on clinical trial data and epidemiological studies. Vaccination for women aged 20-45 can effectively induce the production of antibodies and reduce the risk of persistent high-risk HPV infection. The vaccine is more effective in protecting women who are not infected with HPV, but those who are already infected may still benefit. The vaccination needs to be completed in 3 doses. The interval between the second dose and the first dose is 1-2 months, and the interval between the third dose and the first dose is 6 months. Routine HPV testing is not required before vaccination, but it is recommended to complete cervical cancer screening to ensure that there are no existing lesions. Common adverse reactions include pain, redness, swelling, or low-grade fever at the injection site, which usually resolve spontaneously within a short period of time. Pregnant women should postpone vaccination, and lactating women should be carefully evaluated.

It is recommended that women of appropriate age be vaccinated as early as possible if there are no contraindications, and at the same time undergo regular combined cervical TCT and HPV screening. Maintaining a single sexual partner and using condoms can further reduce the risk of infection. After vaccination, you still need to pay attention to symptoms such as abnormal vaginal bleeding, and seek medical treatment in time to check for lesions.